ArticleJournal for immunotherapy of cancer2019

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.

Hans-Georg Rammensee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.